genkonstrukt to activation of arzneimittelvorstufen, a heterologous,glycosylphophatidylinositol - modified carboxypeptidase g2 and a cell surface - oriented signalpeptid encoded

摘要

This invention relates particularly to gene directed enzyme prodrug therapy (GDEPT) using post translational glycosylphosphatidylinositol (GPI addition to a prodrug activating enzyme to enable anchorage of the enzyme at the cell surface, particularly for use in cancer therapy. A preferred prodrug activating enzyme is carboxypeptidase G2.